ALK is a RTK that can be implicated as truncated fusion protein and full-length kinase in a number of solid and haematologic malignancies, and in most cases its inhibition leads to a marked decrease of tumour cells growth and survival [28,29,30,31,32]. Here, ALK is linked to neoplasm.